Nanjing, China

Hanmei Xu

USPTO Granted Patents = 11 

 

 

Average Co-Inventor Count = 1.4

ph-index = 1


Location History:

  • Jiangsu, CN (2018)
  • Nanjing, CN (2016 - 2024)

Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Hanmei Xu: Innovator in Biopharmaceuticals

Introduction

Hanmei Xu is a prominent inventor based in Nanjing, China, known for his significant contributions to the field of biopharmaceuticals. With a total of 11 patents to his name, Xu has made remarkable advancements in the development of polypeptides that address various medical conditions.

Latest Patents

Among his latest patents, Xu has developed a polypeptide that is utilized for treating various fibrosis diseases and symptoms. This polypeptide comprises specific amino acid domains, including Pro-Arg-Cys-X-Y-Gly-Glu, where X is Trp or Tyr, and Y is Arg or Cys. It has shown potential in treating conditions such as pulmonary fibrosis, hepatic fibrosis, myelofibrosis, renal fibrosis, myocardial fibrosis, skin fibrosis, and lung tissue lesions. Another notable patent involves a polypeptide with anti-aging activity, which is capable of prolonging lifespan and enhancing movement behavior. This polypeptide has an amino acid sequence of XKFAA and retains its beneficial properties even after modifications.

Career Highlights

Hanmei Xu has worked with several companies, including Nanjing Anji Biological Technology Co., Ltd and Jiangsu Rongtai Biotech Co., Ltd. His work in these organizations has contributed to the advancement of biopharmaceutical research and development.

Collaborations

Xu has collaborated with notable coworkers, including Chunyan Pu and Zhian Kang, further enhancing the impact of his research in the biopharmaceutical field.

Conclusion

Hanmei Xu's innovative work in the development of polypeptides showcases his dedication to improving medical treatments and addressing significant health challenges. His contributions continue to influence the biopharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…